Citation Impact
2 from Science/Nature 93 standout
Citing Papers
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
Upadacitinib Induction and Maintenance Therapy for Crohn’s Disease
2023 Standout
Works of Steven Jungerwirth being referenced
Efficacy and Safety of ABT‐494, a Selective JAK‐1 Inhibitor, in a Phase IIb Study in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate
2016
A Phase IIb Study of ABT‐494, a Selective JAK‐1 Inhibitor, in Patients With Rheumatoid Arthritis and an Inadequate Response to Anti–Tumor Necrosis Factor Therapy
2016
Author Peers
| Author | Rheumatology | PFM | Oncology | Hematology | Last Decade | Papers | Cites |
|---|---|---|---|---|---|---|---|
| Steven Jungerwirth | 261 | 27 | 155 | 133 | 8 | 476 | |
| Toru Uehara | 4 | 3 | 4 | 51 | 1.4k | ||
| L. Muijres | 6 | 330 | |||||
| Pingbo Wang | 3 | 22 | 307 | ||||
| Rongcai Liang | 2 | 4 | 8 | 2 | 20 | 337 | |
| W. R. Burris | 3 | 2 | 24 | 324 |
All Works
Loading papers...